Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of IAP0971 in advanced malignant tumors
CTR20240077Phase 2Active
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Jan 2024
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IAP0971 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by SUNHO BioPharmaceutical. Started Jan 2024; status: active.
02
Drugs
IAP0971
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240077.